Ticagrelor Ticagrelor Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y receptor. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high
Pyrophosphoric acid red heat of a sodium phosphate salt. It was found that phosphoric acid when heated to red heat formed pyrophosphoric acid that was readily converted to phosphoric acid by hot water. Pyrophosphoric acid Pyrophosphoric acid, also known under the name diphosphoric acid, is colorless, odorless, hygroscopic and is soluble in water, diethyl ether, and ethyl alcohol. The anhydrous acid has two different forms, which melt at 54.3 °C and 71.5 °C. It is best prepared by ion exchange from sodium pyrophosphate or by reacting hydrogen sulfide with lead pyrophosphate. When phosphoric acid is dehydrated pyrophosphoric acid is produced as one